会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • 콜라겐-자극혈소판응집에대한억제제
    • 콜라겐 - 자극혈소판응집에대한억제제
    • KR100445309B1
    • 2004-11-12
    • KR1019950700766
    • 1994-06-28
    • 메르크 파텐트 게엠베하
    • 햄베르게르,위르겐멜쩨,구이도
    • C07K14/81A61K38/17
    • C07K14/43536A61K38/00A61K39/00Y10S514/822Y10S530/855Y10S530/858
    • PCT No. PCT/EP94/02087 Sec. 371 Date Feb. 28, 1995 Sec. 102(e) Date Feb. 28, 1995 PCT Filed Jun. 28, 1994 PCT Pub. No. WO95/01375 PCT Pub. Date Jan. 12, 1995A protein isolated from crude extracts of Hirudo medicinalis is disclosed, which strongly inhibits the binding to collagen of platelets and their subsequent activation, which leads to platelet aggregation and thrombus formation. Additionally the protein prevents binding of von Willebrand factor to collagen. Described is a method for isolation and purification of the protein as well as its use for blocking collagen-stimulated platelet aggregation. The new protein (Brandinin) has a molweight of approximately 15 kD, binds to collagen but has no collagen-cleaving activity. The protein is useful in the prophylaxis, prevention and treatment of thrombotic diseaeses and for coating of blood-contacting materials, rendering them thromboresistant.
    • PCT No.PCT / EP94 / 02087 Sec。 371日期1995年2月28日Sec。 102(e)日期1995年2月28日PCT申请日1994年6月28日PCT Pub。 No. WO95 / 01375 PCT Pub。 日期1995年1月12日公开了从水蛭粗提取物中分离出的蛋白质,其强烈抑制与血小板胶原的结合及其随后的活化,这导致血小板聚集和血栓形成。 此外,该蛋白可防止冯维勒布兰德因子与胶原蛋白结合。 描述了分离和纯化蛋白质的方法以及其用于阻断胶原刺激的血小板聚集的用途。 新蛋白质(Brandinin)的摩尔质量约为15 kD,与胶原蛋白结合,但没有胶原蛋白切割活性。 该蛋白质可用于预防,预防和治疗血栓形成性病变,并用于血液接触材料的涂层,使其抗血栓形成。
    • 10. 发明授权
    • 콜라겐-자극 혈소판 응집을 위한 단백질 및 이로 코팅된의료 기기
    • 콜라겐 - 자극혈소판응집을위한단백질및이로코팅된의료기기
    • KR100455639B1
    • 2004-11-09
    • KR1020047002282
    • 1994-06-28
    • 메르크 파텐트 게엠베하
    • 햄베르게르위르겐멜쩌구이도
    • A61L33/04
    • C07K14/43536A61K38/00A61K39/00Y10S514/822Y10S530/855Y10S530/858
    • PCT No. PCT/EP94/02087 Sec. 371 Date Feb. 28, 1995 Sec. 102(e) Date Feb. 28, 1995 PCT Filed Jun. 28, 1994 PCT Pub. No. WO95/01375 PCT Pub. Date Jan. 12, 1995A protein isolated from crude extracts of Hirudo medicinalis is disclosed, which strongly inhibits the binding to collagen of platelets and their subsequent activation, which leads to platelet aggregation and thrombus formation. Additionally the protein prevents binding of von Willebrand factor to collagen. Described is a method for isolation and purification of the protein as well as its use for blocking collagen-stimulated platelet aggregation. The new protein (Brandinin) has a molweight of approximately 15 kD, binds to collagen but has no collagen-cleaving activity. The protein is useful in the prophylaxis, prevention and treatment of thrombotic diseaeses and for coating of blood-contacting materials, rendering them thromboresistant.
    • PCT No.PCT / EP94 / 02087 Sec。 371日期1995年2月28日Sec。 102(e)日期1995年2月28日PCT申请日1994年6月28日PCT Pub。 No. WO95 / 01375 PCT Pub。 日期1995年1月12日公开了从水蛭粗提取物中分离出的蛋白质,其强烈抑制与血小板胶原的结合及其随后的活化,这导致血小板聚集和血栓形成。 此外,该蛋白可防止冯维勒布兰德因子与胶原蛋白结合。 描述了分离和纯化蛋白质的方法以及其用于阻断胶原刺激的血小板聚集的用途。 新蛋白质(Brandinin)的摩尔质量约为15 kD,与胶原蛋白结合,但没有胶原蛋白切割活性。 该蛋白质可用于预防,预防和治疗血栓形成性病变,并用于血液接触材料的涂层,使其抗血栓形成。